Orexigen grabs $22M from Takeda, Kwang Dong; Invitae leases SF building;

@FierceBiotech: FierceBiotech Radio with @JohnCFierce on Turing Pharma, Martin Shkreli and the magic of Twitter. More | Follow @FierceBiotech

@JohnCFierce: These Twitter controversies are intense. On CNN, Sky News, CBC and other radio shows to discuss being called a moron. Cheers. | Follow @JohnCFierce

@DamianFierce: The best thing about ABC's exclusive Shkreli story was that NBC ran it 15 minutes earlier. | Follow @DamianFierce

> Orexigen ($OREX) says it nailed the first of three potential $15 million milestone payments from Takeda. The San Diego-based biotech also grabbed a $7 million upfront payment from Kwang Dong Pharmaceutical Company, which is based in Seoul. Release

> The DNA testing giant Invitae ($NVTA) has leased the Potrero Hill Building in San Francisco, according to the local business journal. Story

Medical Device News

@FierceMedDev: ICYMI: St. Jude nabs CE mark for Infinity DBS for movement disorders, awaits U.S. launch before year end. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceBiotech: Should Martin Shkreli be allowed to play the Good Samaritan defense? Commentary | Follow @VarunSaxena2

@EmilyWFierce: Human Longevity joins with South African insurer for $250 exome sequencing service. FierceDiagnostics article | Follow @EmilyWFierce

> CliniCloud gets $5M seed round to launch connected medical kit at Best Buy. News

> Institute of Medicine makes suggestions for improving accuracy of medical diagnoses. Item

> Four key medical device recalls of 2015. Report

Pharma News

@FiercePharma: Otsuka prepares to roll out two-drug combo for colorectal cancer. FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: ICYMI: Novo to build a $78M insulin pen plant in Iran. FiercePharmaManufacturing story | Follow @EricPFierce

> Top-selling drugs might be first in line for Medicare price negotiations. News

> Hillary Clinton plan to curb drug prices puts the screws to drugmakers and insurers. Story

> EP Vantage: Legal loopholes, price hikes set up aging meds for billions in 2020. Article

Biotech Research News

> Uppsala's 'smart' robot tests new cancer drug combos. News

> Epigenomic combo shows promise in mouse model of pancreatic cancer. Story

> An arthritis drug demos potential to help reverse Alzheimer's disease. More

> Experimental drug amps up Afinitor's punch against pancreatic cancer. Article

> Imperial team targets a key culprit involved in Parkinson's. News

Diagnostics News

> Roche's influenza A and B tests get federal permission to be used at the point-of-care. Story

> LabCorp, China's Fosun Pharma, lead Asia-heavy $15B investment in Ativa Medical. More

> Rumor: Private equity owners looking to sell Swiss diagnostics player Unilabs for $1.7B. Article

> Human Longevity joins with South African insurer for $250 exome sequencing service. News

> Sequenom appoints new CEO amid diversification. Story

Pharma Marketing News

> Emmy co-host Mario Lopez spotlights Valeant's Jublia on the red carpet. News

> Fretting about potential Humira pain for AbbVie? Take heart in potential cost cuts. Story

> Apple's ad blocking heats up debate, but what does it mean for pharma? Article

> IMS Health finds mHealth mobile app 'prescriptions' on the rise. Story

> Otsuka prepares to roll out two-drug combo for colorectal cancer. Item

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.